A Phase 3 Randomized Double-Blind Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
Brief description of study
This is a Phase 3, randomized, placebo- and active-controlled, parallel-group, multicenter, double-blind safety and efficacy study of adjuvant V940 plus pembrolizumab (Arm A) versus adjuvant placebo plus pembrolizumab (Arm B) in participants with completely resected high-risk (Stage II-IV [including clinical Stage II] per AJCC eighth edition) cutaneous melanoma (Appendix 9). Participants must not have received any prior systemic therapy for their melanoma beyond surgical resection.
Clinical Study Identifier: s23-00520
ClinicalTrials.gov Identifier: NCT05933577
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
